The global molecular diagnostics market was valued at USD 18.8 billion in 2025. It is projected to reach USD 19.4 billion in 2026 and USD 25.6 billion by 2033, growing at a CAGR of 4.1% from 2026 to 2033, according to Grand View Research. North America led with a 44.1% revenue share in 2025.

That growth is steady rather than explosive. Most of the value is concentrated in a few places: recurring-use reagents, PCR workflows and infectious disease testing.

Market Breakdown & Key Segments

Where the money sits

The molecular diagnostics market is a consumables business with an instrument business attached. Reagents held 65.5% of the market in 2025 and are forecast to grow fastest, at a 4.3% CAGR. Enzymes, probes, primers and buffers are used up with every run on PCR, NGS and digital PCR platforms.

Reagent growth (4.3%) is slightly ahead of overall growth (4.1%). My read is that, over time, consumables will take a bigger share of revenue than hardware.

Segment leaders at a glance: In 2025, reagents led the product category with a 65.5% share and are also the fastest-growing product, at a 4.3% CAGR. PCR led the technology category with 62.2%, while ISH is the fastest-growing technology. Central laboratories hold the largest share by test location, but self-test and OTC formats are growing fastest. Infectious disease is the largest application, and oncology is expanding the quickest.

Download a free sample report or claim your copy of this full market intelligence report

Technology: PCR is the default, with others rising

PCR's 62.2% share reflects its range, from quantitative and reverse transcription PCR to multiplex formats that detect several targets at once. Digital PCR is the premium tier. Thermo Fisher's QuantStudio Absolute Q AutoRun dPCR Suite and Roche's Digital LightCycler System both target cancer detection.

In situ hybridization (ISH) is growing fastest, helped by newer probes for B-cell lymphoma and HPV detection.

Applications: infection leads, cancer accelerates

Infectious disease testing is the largest application because PCR and NGS have replaced slower culture-based methods for diseases such as tuberculosis and HIV. Oncology is the fastest-growing application. The report projects global cancer cases to reach 30 million new cases by 2040, which keeps demand for biomarker identification, treatment selection and disease monitoring rising.

The access question

Price is the main restraint on the molecular diagnostics market. Bio-Rad's CFX Connect PCR system costs about USD 17,995. Manual digital PCR instruments run roughly USD 65,000-70,000, and automated systems can exceed USD 100,000. That gap explains why mature economies adopt advanced platforms first.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Regional Analysis

North America: scale and infrastructure

North America's 44.1% share comes from advanced healthcare infrastructure, supportive regulation and active pharma-diagnostics partnerships. The report puts the U.S. at an 84.3% revenue share in 2025. Demand is backed by disease burden: the American Cancer Society projected more than 2 million new U.S. cancer cases in 2024, and CDC data shows about 129 million Americans living with at least one major chronic condition.

Canada is following the same pattern. Projected new cancer diagnoses rose from 239,100 in 2023 to 247,100 in 2024.

Europe: aging and heart disease

In Europe, cardiovascular disease drives testing demand, accounting for more than 42.5% of annual deaths in the WHO European Region. In Germany, roughly one in 20 people is over 80, and that is projected to reach one in six by 2050. In the UK, the 2024 rollout of community diagnostic centres in England aims to cut waiting lists.

Asia Pacific: the fastest-growing region

Asia Pacific has the highest forecast CAGR from 2026 to 2033. The WHO South-East Asia Region accounts for more than 45% of global TB incidence, with over 4.8 million cases in 2022, so rapid molecular TB testing has an obvious use. China adds to this with rising healthcare spending, an aging population and heavy investment in genomics.

Latin America and the Middle East & Africa

Latin America is growing through multinational investment and rising R&D spending. In June 2025, Roche Diagnostics Mexico introduced a rapid TB test and an oncology sequencing system. In the Middle East and Africa, cancer incidence in the Middle East was expected to double by 2030 from 2020 levels. About 9 of the 22 countries in the region lacked optimal cancer-management facilities, and Saudi Arabia recorded more than 4.27 million people with diabetes in 2021.

Key Industry Players

The report profiles 16 companies: BD, bioMérieux, Bio-Rad, Abbott, Agilent, Danaher, Hologic, Illumina, Grifols, QIAGEN, Roche, Siemens Healthineers, Sysmex, Seegene, EliTechGroup and CERTEST BIOTEC.

The report splits them into two camps:

• Mature players (such as BD) win on installed instrument bases, broad assay menus and regulatory track records. Their weakness is high pricing in emerging markets.
• Emerging players (such as Seegene) win on speed, open-platform assays and customizable multiplex panels, but have limited distribution and manufacturing scale.

Recent moves show where the competition is heading:

• Consolidation: Abbott completed its roughly USD 21 billion acquisition of Exact Sciences in March 2026, strengthening its cancer screening position.
• Automation: QIAGEN launched QIAsprint Connect (February 2026) and QIAsymphony Connect (August 2026) to automate nucleic-acid extraction.
• Outbreak speed: Roche reported developing a research-use PCR test for Bundibugyo Ebola in six days in June 2026.
• Access: WHO prequalified the BD Onclarity HPV Assay in October 2025, with self-collection support for low- and middle-income countries.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Emerging Trends

Decentralized and self-testing. The Texas self-collected HPV screening pilot, run with MD Anderson, shows molecular testing moving into underserved communities. Self-test/OTC is the fastest-growing test location.

Liquid biopsy and NGS. Blood-based cancer detection through circulating DNA is attracting investment, and NGS is expanding across oncology. QIAGEN's QIAcuityDx digital PCR system (September 2024) targets liquid biopsy monitoring.

AI-assisted interpretation. NGS produces far more data than manual analysis can handle. AI and machine learning can speed up the identification of clinically relevant mutations and biomarkers. Ataraxis AI's USD 4 million seed round (October 2024) is one example.

Regulatory friction. Proposed FDA oversight of laboratory-developed tests has raised concern among Yale experts that it could limit access to diagnostics for rare diseases.

Check Out Our Dedicated Business Offerings – 

• Healthcare Facility Mapping & Intelligence Platform: Map and analyze U.S. healthcare facilities. Explore now
• Prism AI: Get market intelligence backed by cited research. Try Prism AI